Kyxata is a drug owned by Avyxa Holdings Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 01, 2045. Details of Kyxata's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12427104 | NA |
Apr, 2045
(19 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Kyxata's patents.
Latest Legal Activities on Kyxata's Patents
Given below is the list of recent legal activities going on the following patents of Kyxata.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification | 18 Sep, 2025 | US12427104 |
| Issue Notification Mailed | 17 Sep, 2025 | US12427104 |
| Application Is Considered Ready for Issue | 08 Sep, 2025 | US12427104 |
| Dispatch to FDC | 08 Sep, 2025 | US12427104 |
| Email Notification | 05 Sep, 2025 | US12427104 |
| Mail Response to 312 Amendment (PTO-271) | 05 Sep, 2025 | US12427104 |
| Response to Amendment under Rule 312 | 02 Sep, 2025 | US12427104 |
| Pubs Case Remand to TC | 29 Aug, 2025 | US12427104 |
| Amendment after Notice of Allowance (Rule 312) | 28 Aug, 2025 | US12427104 |
| Issue Fee Payment Received | 28 Aug, 2025 | US12427104 |
US patents provide insights into the exclusivity only within the United States, but
Kyxata is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Kyxata's family patents as well as insights into
ongoing legal events
on those patents.
Kyxata's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kyxata's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 01, 2045 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kyxata Generic API suppliers:
Carboplatin is the generic name for the brand Kyxata. 23 different companies have already filed for the generic of Kyxata, with Fresenius Kabi Usa having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Kyxata's generic
About Kyxata
Kyxata is a drug owned by Avyxa Holdings Llc. Kyxata uses Carboplatin as an active ingredient. Kyxata was launched by Avyxa in 2025.
Approval Date:
Kyxata was approved by FDA for market use on 08 August, 2025.
Active Ingredient:
Kyxata uses Carboplatin as the active ingredient. Check out other Drugs and Companies using Carboplatin ingredient
Dosage:
Kyxata is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 80MG/8ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 20MG/2ML (10MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 500MG/50ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |